Apolipoprotein C-III SstI genotypes modulate exercise-induced hypotriglyceridemia

Medicine and Science in Sports and Exercise

Volumn 36, Issue 6, 2004, Pages 955-959

  Woo, Sang Koo ^a   Kang, Hyun Sik ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

Body mass index; Exercise; Genotype; Lipoprotein lipids; Waist circumference

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESTRICTION ENDONUCLEASE; TRIACYLGLYCEROL; TYPE I SITE SPECIFIC DEOXYRIBONUCLEASE;

ADULT; AGE; ANALYSIS OF VARIANCE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BICYCLE ERGOMETER; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; EXERCISE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LINEAR REGRESSION ANALYSIS; MALE; NORMAL HUMAN; PATIENT SELECTION; PREDICTION; SCORING SYSTEM; SMOKING; SOUTH KOREA; TREADMILL ERGOMETRY; TREATMENT PLANNING; WAIST CIRCUMFERENCE;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; BASE SEQUENCE; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA PRIMERS; EXERCISE; GENOTYPE; HUMANS; KOREA; MALE; TRIGLYCERIDES;

EID: 2642544952     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1249/01.MSS.0000128200.38372.82     Document Type: Article

References (39)

1. AALTO-SETALA, K., E. A. FISHER, X. CHEN, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles. J. Clin. Invest. 90:1889-1900, 1992.
2. AALTO-SETALA, K., P. H. WEINSTOCK, C. L. BISGAIER, L. WU, J. D. SMITH, and J. L. BRESLOW. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse transgenic mice. J. Lipid Res. 37:1802-1811, 1996.
3. AUWERX, J., K. SCHOONJANS, J.-C. FRUCHART, and B. STAELS. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis 124:S29-S37, 1996.
4. BATAL, R., M. TREMBLAY, P. H. R. BARRETT, et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 41:706-718, 2000.
5. BRESLOW, J. L. Familial disorders of high density lipoprotein metabolism. In: The Metabolic Basis of Inherited Disease, C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (Eds.). New York: McGraw-Hill, 1995, pp. 1251-1266.
6. CEESAY, S. M., A. M. PRENTICE, K. C. DAY, et al. The use of heart rate monitoring in the estimation of energy expenditure: a validation study using indirect whole-body calorimetry. Br. J. Nutr. 61:175-186, 1989.
7. CHHABRA, S., R. NARANG, L. R. KRISHNAN, et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet. 3:1-6, 2002.
8. DAMMERMAN, M., L. A. SANDKUIJL, J. L. HALLAS, W. CHUNG, and J. L. BRESLOW. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA 90:4562-4566, 1993.
9. DE SILVA, H. V., S. J. LAUER, J. WANG, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein. Eur. J. Biochem. 269:2324-2335, 1994.
10. DURSTINE, J. L., P. W. GRANDJEAN, C. A. Cox, and P. D. THOMPSON. Lipids, lipoproteins, and exercise. J. Cardiopulm. Rehabil. 22: 385-398, 2002.
11. FREDENRICH, A., L. M. GIROUX, M. TREMBLAY, L. KRIMBOU, J. DAVIGNON, and J. S. COHN. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apo-E ratio in different lipoprotein fractions. J. Lipid Res. 38:1421-1432, 1997.
12. FRIEDEWALD, W. T., R. I. LEVY, and D. S. FREDRICKSON. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:499-502, 1972.
13. GAME, F. L., and A. F. JONES. Coronary heart disease risk assessment in diabetes mellitus: a comparison of PROCAM and Framingham risk assessment functions. Diabetes Med. 18:355-359, 2001.
14. GERVAISE, N., M. A. GARRIGUE, G. LASFARGUES, and P. LECOMTE. Triglycerides, apoC3 and LpB:C3 and cardiovascular risk in type II diabetes. Diabetologia 43:703-708, 2000.
15. GINSBERG, H. N., N. A. Le, I. J. GOLDBERG, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78:1287-1295, 1986.
16. GROENENDIJK, M., R. M. CANTOR, T. W. A. DE BRUIN, and G. M. DALLINGA-THIE. The apoAI-CIII-AIV gene cluster. Atherosclerosis 157:1-11, 2001.
17. HENDERSON, H. E., S. V. LANDEN, J. MICHIE, and G. M. B. BERGER. Association of DNA polymorphism in the apolipoprotein CIII gene with diverse hyperlipidaemic phenotypes. Hum. Genet. 75: 62-65, 1987.
18. HIXSON, J. E., D. T. VERNIER, and P. K. POWERS. Detection of SstI restriction site polymorphism in human APOC3 by the polymerase chain restriction. Nucleic Acids Res. 19:196, 1991.
19. HONG, S. H., W. H. PARK, C. C. LEE, J. H. SONG, and J. Q. KIM. Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemia subjects. Clin. Chem. 43:13-17, 1997.
20. ITO, Y., N. AZROLAN, A. O' CONNELL, A. WALSH, and J. L. BRESLOW. Hypertriglyceridemia as a result of human apo C-III gene expression in transgenic mice. Science 249:790-793, 1990.
21. JONG, M. C., P. C. N. RENSEN, V. E. H. DAHLMANS, H. VAN DER BOOM, T. J. C. VAN BERKEL, and L. M. HAVEKES. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid Res. 42: 1578-1585, 2001.
22. KANG, H. S., B. GUTIN, P. BARBEAU, M. S. LITAKER, J. ALLISON, and N. A. LE. Low-density lipoprotein particle size, central obesity, cardiovascular fitness, and insulin resistance syndrome markers in obese youths. Int. J. Obes. 26:1030-1035, 2002.
23. KANG, H. S., B. GUTIN, P. BARBEAU, et al. Physical training improves insulin resistance syndrome markers in obese adolescents. Med. Sci. Sports Exerc. 34:1920-1927, 2002.
24. KARATHANASIS, S. K. Apolipoprotein multigene family: tandem organization of human apolipoprotein Ai, CIII, and AIV genes. Proc. Natl. Acad. Sci. USA 82:6374-6378, 1985.
25. MAEDA, N., H. Li, D. LEE, P. OLIVER, S. H. QUARFORDT, and J. OSADA. Targeted disruption of the apolipoprotein C-III gene in mice results in hypertriglyceridemia and protection from postprandial hypertriglyceridemia. J. Biochem. 269:23610-23616, 1994.
26. ORDOVAS, J. M., F. CIVEIRA, J. GENEST, et al. Restriction fragment length polymorphism of the apolipoprotein A-I, C-III, A-IV gene locus: relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 87:75-86, 1991.
27. PAUL-HAYASE, H., M. ROSSENEU, D. ROBINSON J. P. VAN BERVLIET, J. P. DESLYPERE, and S. E. HUMPHRIES. Polymorphisms in the apolipoprotein (apo) AI-CIII-AIV gene cluster: detection of genetic variation determining plasma apo AI, apo CIII and apo AIV concentrations. Hum. Genet. 88:439-446, 1992.
28. PEREIRA, M. A., P. J. SCHREINER, J. S. PANKOW, et al. The family risk score for coronary heart disease: associations with lipids, lipoproteins, and body habitus in a middle-aged bi-racial cohort: the ARIC study. Ann. Epidemiol. 10:239-245, 2000.
29. SHOULDERS, C. C., P. J. HARRY, L. LAGROST, et al. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Arterosclerosis 87:239-247, 1991.
30. SMITH, J. D., E. A. BRINTON, and J. L. BRESLOW. Polymorphism in the human apolipoprotein A-I gene promoter region: association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J. Clin. Invest. 89:1796-1800, 1992.
31. STOCKS, J., H. PAUL-HAYASE, and D. J. GALTON. Haplotypes identified by DNA restriction-fragment-length polymorphisms in the AI-C-III-A-IV gene region and hypertriglyceridemia. Am. J. Hum. Genet. 41:106-118, 1987.
32. SURGUCHOV, A. P., G. P. PAGE, L. SMITH, W. PATSCH, and E. BOERWINKLE. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler. Thromb. Vasc. Biol. 16:941-947, 1996.
33. TAS, S. Strong association of a single nucleotide substitution in the 3′-untranslated region of the apolipoprotein CIII gene with common hypertriglycedemia in Arabs. Clin. Chem. 35:256-259, 1989.
34. THOMPSON, P. D., E. M. CULLINANE, S. P. SADY, et al. Modest changes in HDL concentration and metabolism with prolonged exercise training. Circulation 78:25-34, 1988.
35. TILLY, P., C. SASS, M. VINCENT-VIRY, D. AGUILLON, G. SIEST, and S. VISVIKIS. Biological and genetic determinants of serum apo C-III concentration: reference limits from the Stanislas cohort. J. Lipid Res. 22:4430-436, 2003.
36. TYBJAERG-HANSEN, A., B. G. NORDESTGAARD, L. U. GERDES O. FAERGEMAN, and S. E. HUMPHRIES. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 100:157-169, 1993.
37. WANG, C. S., W. J. MCCONATHY, H. U. KLOER, and P. ALAUPOVIC. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J. Clin. Invest. 75:384-390, 1985.
38. WEINTRAUB, M., Y. ROSEN, R. OTRO, S. EISENBERG, and J. BRESLOW. Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels. Circulation 79:1007-1014, 1989.
39. ZENG, Q., M. DAMMERMAN, Y. TAKADA, A. MATSUNAGA, J. L. BRESLOW, and J. SASAKI. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum. Genet. 95:371-375, 1995.